Institutional Sign In

Go

Novartis Czech Republic

Novartis Czech Republic's Cash & Cash Equivalents fell 100% yoy to CZK 0 mil in 2017

By Helgi Library - April 2, 2020

Novartis Czech Republic's total assets reached CZK 1,898 mil at the end of 2017, up 9.89% compared to the previous year. ...

Novartis Czech Republic's Cash & Cash Equivalents fell 100% yoy to CZK 0 mil in 2017

By Helgi Library - April 2, 2020

Novartis Czech Republic's total assets reached CZK 1,898 mil at the end of 2017, up 9.89% compared to the previous year. ...

Profit Statement
Balance Sheet
Ratios
Cash Flow

Get all company financials in excel:

Download Sample   $19.99

Get all company financials in excel:

Download Sample   $19.99

Novartis Czech Republic Logo

Finance

Novartis Czech Republic has been growing its sales by a year on average in the last 5 years. EBITDA has grown on average by 14.6% a year during that time to total of CZK 138 mil in 2017, or 2.18% of sales. That’s compared to 2.29% average margin seen in last five years.

The company netted CZK 71.0 mil in 2017 implying ROE of 11.5% and ROCE of 5.67%. Again, the average figures were 16.3% and 6.74%, respectively when looking at the previous 5 years.

Novartis Czech Republic’s net debt amounted to CZK 51.2 mil at the end of 2017, or 7.85% of equity. When compared to EBITDA, net debt was 0.371x, up when compared to average of 0.245x seen in the last 5 years.